Medical decision making: Microsimulation versus cohort modelling for assessing type 2 diabetes treatments

Juntao Lyu; Hansoo Kim

doi:10.36334/modsim.2023.lyu

Abstract

Type 2 Diabetes Mellitus (T2DM) is associated with high rates of mortality and complications, making it challenging to evaluate new treatments. Health economic models, such as cohort models and microsimulations, are currently available to evaluate new medications. However, it remains unclear which type of modelling is more suitable for evaluating T2DM treatments. Tirzepatide is a new treatment that has demonstrated promising results for glycaemic control in diabetic patients requiring insulin. The aim of this study is to compare the differences between microsimulation and cohort modelling when assessing tirzepatide for treating type-2 diabetes.

Original language	English
Pages	527-527
Number of pages	1
DOIs	https://doi.org/10.36334/modsim.2023.lyu
Publication status	Published - Jul 2023
Externally published	Yes
Event	25th International Congress on Modelling and Simulation - Darwin Convention Centre, Darwin, Australia Duration: 9 Jul 2023 → 13 Jul 2023 https://www.mssanz.org.au/modsim2023/index.html

Conference

Conference	25th International Congress on Modelling and Simulation
Country/Territory	Australia
City	Darwin
Period	9/07/23 → 13/07/23
Internet address	https://www.mssanz.org.au/modsim2023/index.html

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.36334/modsim.2023.lyuLicence: Free to read

https://www.mssanz.org.au/modsim2023/authorsH-K.html#kLicence: Free to read

Cite this

@conference{d5dc32c8e1ef4f7c8a01c4110d48c076,

title = "Medical decision making: Microsimulation versus cohort modelling for assessing type 2 diabetes treatments",

abstract = "Type 2 Diabetes Mellitus (T2DM) is associated with high rates of mortality and complications, making it challenging to evaluate new treatments. Health economic models, such as cohort models and microsimulations, are currently available to evaluate new medications. However, it remains unclear which type of modelling is more suitable for evaluating T2DM treatments. Tirzepatide is a new treatment that has demonstrated promising results for glycaemic control in diabetic patients requiring insulin. The aim of this study is to compare the differences between microsimulation and cohort modelling when assessing tirzepatide for treating type-2 diabetes. ",

author = "Juntao Lyu and Hansoo Kim",

year = "2023",

month = jul,

doi = "10.36334/modsim.2023.lyu",

language = "English",

pages = "527--527",

note = "25th International Congress on Modelling and Simulation ; Conference date: 09-07-2023 Through 13-07-2023",

url = "https://www.mssanz.org.au/modsim2023/index.html",

}

TY - CONF

T1 - Medical decision making: Microsimulation versus cohort modelling for assessing type 2 diabetes treatments

AU - Lyu, Juntao

AU - Kim, Hansoo

PY - 2023/7

Y1 - 2023/7

N2 - Type 2 Diabetes Mellitus (T2DM) is associated with high rates of mortality and complications, making it challenging to evaluate new treatments. Health economic models, such as cohort models and microsimulations, are currently available to evaluate new medications. However, it remains unclear which type of modelling is more suitable for evaluating T2DM treatments. Tirzepatide is a new treatment that has demonstrated promising results for glycaemic control in diabetic patients requiring insulin. The aim of this study is to compare the differences between microsimulation and cohort modelling when assessing tirzepatide for treating type-2 diabetes.

AB - Type 2 Diabetes Mellitus (T2DM) is associated with high rates of mortality and complications, making it challenging to evaluate new treatments. Health economic models, such as cohort models and microsimulations, are currently available to evaluate new medications. However, it remains unclear which type of modelling is more suitable for evaluating T2DM treatments. Tirzepatide is a new treatment that has demonstrated promising results for glycaemic control in diabetic patients requiring insulin. The aim of this study is to compare the differences between microsimulation and cohort modelling when assessing tirzepatide for treating type-2 diabetes.

U2 - 10.36334/modsim.2023.lyu

DO - 10.36334/modsim.2023.lyu

M3 - Abstract

SP - 527

EP - 527

T2 - 25th International Congress on Modelling and Simulation

Y2 - 9 July 2023 through 13 July 2023

ER -